Tuesday, April 28, 2026, 12:00 PM–1:00 PM ET
Discover how next-day comprehensive genomic profiling (CGP) is possible with the Oncomine Comprehensive Assay Plus on the Genexus System—delivering both speed and accuracy.
Webinar presenters Jane Bayani, MHSc, PhD, Assistant Professor and Co-Director, Diagnostic Development, Ontario Institute for Cancer Research, Canada, and Nicola Normanno, MD, Scientific Director, IRCCS Romagnolo Institute for the Study of Tumors, Italy, and Morten Grauslund, PhD, Molecular Biologist, Department of Pathology, Rigshospitalet/Copenhagen University Hospital, Copenhagen, Denmark.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Thermo Fisher Scientific. For Research Use Only. Not for use in diagnostic applications.
Thursday, April 30, 2026, 11:00 AM–12:00 PM ET
Hear an expert discuss how Memorial Sloan Kettering Cancer Center (MSKCC) is utilizing
the oncoReveal® Nexus 21-gene panel to redefine turnaround time and actionable insights
in cancer care. Dr. Ewalt shares a perceptive look at the clinical need for rapid, front-line NGS sequencing, and how a unique, purpose built targeted NGS panel (Pillar Biosciences’ oncoReveal Nexus 21 gene Panel) was developed, validated and implemented clinically by Memorial Sloan Kettering Cancer Center (MSK-REACT) to complement their current comprehensive genomic profiling (CGP) approach.
Webinar presenter Mark Ewalt, MD, Associate Medical Director for Laboratory Operations for Diagnostic Molecular Pathology in the Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, MSKCC.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Pillar Biosciences.
Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
July 3, 2025—The FDA has approved Thermo Fisher Scientific’s Oncomine Dx Express test on the Ion Torrent Genexus Dx integrated sequencer as an in vitro diagnostic assay for use as a companion diagnostic for Dizal’s Zegfrovy (sunvozertinib) to identify patients with non-small cell lung cancer harboring EGFR exon 20 insertion mutations.
July 1, 2025—PathAI has received 510(k) clearance from the U.S. Food and Drug Administration for its AISight Dx digital pathology image-management system for use in primary diagnosis in clinical settings.
June 30, 2025—Datroway (datopotamab deruxtecan-dlnk) has been approved in the United States for the treatment of adult patients with locally advanced or metastatic EGFR-mutated non-small cell lung cancer who have received prior EGFR-directed therapy and platinum-based chemotherapy.
June 24, 2025—Bio-Rad Laboratories will present an array of clinical diagnostic-related offerings at this year’s Association for Diagnostics and Laboratory Medicine Clinical Lab Expo in Chicago, July 27–31.
June 18, 2025—BioMérieux will acquire Day Zero Diagnostics, an infectious disease diagnostics company, with the aim of enhancing BioMérieux’s capabilities in next-generation sequencing and rapid diagnostics.
June 17, 2025—StaffReady has released a mobile app for its StaffReady Scheduling.
June 16, 2025—Proscia has published a report in which it partnered with the Dark Intelligence Group to survey more than 360 senior professionals representing independent, hospital, and academic laboratories.
June 13, 2025—Sysmex America has received FDA clearance for its CN-6000 automated blood coagulation analyzer.
June 12, 2025—Seegene will unveil Cureca, a next-generation system designed to streamline automation in polymerase chain reaction testing, on July 30 at ADLM 2025, in Chicago (July 27–31).
June 9, 2025—MeMed announced that more than 100,000 patients have been tested with MeMed BV, the company’s flagship diagnostic that distinguishes between bacterial and viral infections based on the body’s immune response.
